Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $190.6 million.

  • Amicus Therapeutics' Cash & Equivalents fell 1842.39% to $190.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.6 million, marking a year-over-year decrease of 1842.39%. This contributed to the annual value of $213.8 million for FY2024, which is 1345.86% down from last year.
  • Amicus Therapeutics' Cash & Equivalents amounted to $190.6 million in Q3 2025, which was down 1842.39% from $158.7 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Cash & Equivalents registered a high of $385.9 million during Q3 2021, and its lowest value of $148.8 million during Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $211.3 million (2023), whereas its average is $219.3 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Cash & Equivalents surged by 8321.28% in 2021, and later crashed by 3930.88% in 2022.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Cash & Equivalents stood at $245.2 million in 2021, then tumbled by 39.31% to $148.8 million in 2022, then skyrocketed by 65.98% to $247.0 million in 2023, then decreased by 13.46% to $213.8 million in 2024, then dropped by 10.83% to $190.6 million in 2025.
  • Its Cash & Equivalents stands at $190.6 million for Q3 2025, versus $158.7 million for Q2 2025 and $181.7 million for Q1 2025.